Virax Biolabs Group Ltd. has announced the closing of a $5 million private placement of its securities. The company sold and issued 12,500,000 ordinary shares (or equivalents) and preferred investment options to purchase up to 12,500,000 ordinary shares at a combined purchase price of $0.3999 per pre-funded warrant and accompanying preferred investment option. The pre-funded warrants have an exercise price of $0.0001 per share and do not expire, while the preferred investment options have an exercise price of $0.40 per ordinary share and are exercisable for five years from the effective date of the initial registration statement. The offering, facilitated by H.C. Wainwright & Co. as the exclusive placement agent, was made in a private placement exempt from registration under the Securities Act. Virax intends to use the net proceeds for working capital, extending its cash runway into the first half of 2028.